Capstone swings to operating income of USD 432,000 in Q2 FY26; net sales rise 67% to USD 21.48 million - CAPS News | RalliesCapstone swings to operating income of USD 432,000 in Q2 FY26; net sales rise 67% to USD 21.48 million
C
CAPS• Q2 FY26 results
- Capstone Therapeutics posted Q2 net sales of USD 21.48 million, up 67% year over year.
- Net loss widened to USD 1.38 million; operating income swung to USD 432,000 from an operating loss.
- Gross profit climbed to USD 6 million; gross margin rose 3.5 percentage points to 27.9%.
- Interest and other expense widened to USD 1.96 million; SG&A increased 63% to USD 5.51 million.
- Management cited acquisition contributions, a USD 438,000 tariff refund, and higher-margin Carolina Stone mix as key drivers.
•
